There are currently 24 active clinical trials seeking participants for Non-Alcoholic Fatty Liver Disease research studies. The states with the highest number of trials for Non-Alcoholic Fatty Liver Disease participants are Texas, California, Florida and Arizona.
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT06133101
Recruiting
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do not expect any adverse endocrine or metabolomic effects from the consumption of soy isoflavones.
Gender:
ALL
Ages:
Between 5 years and 12 years
Trial Updated:
08/19/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Fibrosis Lessens After Metabolic Surgery
NCT06374875
Recruiting
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/18/2025
Locations: Banner Health Center, Phoenix, Arizona +21 locations
Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Register for Updates
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075
Recruiting
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help. Objective: To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide. Eligibility: People with NAFLD and healthy volunteers ages 18 and older Design: Participants will be screened with: Medical history Physical exam... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Register for Updates
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186
Recruiting
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well peopl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/14/2025
Locations: The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0149), Chandler, Arizona +64 locations
Conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
Register for Updates
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT05463796
Recruiting
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/04/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Register for Updates
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NCT06138821
Recruiting
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Metabolic Disease
Register for Updates
Human Models of Selective Insulin Resistance: Alpelisib, Part I
NCT06354088
Recruiting
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin. Researchers will compare the impac... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/25/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Register for Updates
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
NCT06571474
Recruiting
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals. Both groups will have: * screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \[MRI\] and... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/16/2025
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
Register for Updates
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
NCT06113003
Recruiting
Persons with human immunodeficiency virus (HIV) have higher risk of developing fatty liver disease (NAFLD) than HIV-negative persons but the reasons for this discrepancy are not known. Changes in the intestinal microbiome may contribute to the development of NAFLD in persons with HIV (PWH) through impairment of barrier function of the intestinal wall and by producing metabolites that are harmful to the liver. This project will test the hypothesis that HIV-related NAFLD is associated with differe... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/02/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: HIV, Non-Alcoholic Fatty Liver Disease, Metabolic-Associated Steatotic Liver Disease
Register for Updates
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
NCT05067621
Recruiting
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.
Gender:
ALL
Ages:
Between 10 years and 21 years
Trial Updated:
05/15/2025
Locations: Pediatric Diabetes Center, New Haven, Connecticut
Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Register for Updates
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
NCT05268042
Recruiting
This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restricted control diet. This 6-month study will have 2 phases: a 12-week controlled feeding phase and a 12-week "free living" phase. During the controlled feeding phase, all food will be provided to the families of the participants for the entirety of the 12 weeks. Participants (n=80) will have been diagnosed with NAFLD based on the presence of current evidence of active disease, wh... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Non-Alcoholic Fatty Liver Disease, Obesity
Register for Updates
The Olmsted NAFLD Epidemiology Study (TONES)
NCT04365855
Recruiting
Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate models of NAFLD diagnosis and determine long-term outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Register for Updates